Cost-savings Report
Choose Area(s)
It’s easy to work out potential savings with Zeroderma. Just select your health economy area(s) for instant access to a savings report.
Report prepared for
Area name(s)
There are around xx,xxx of annual savings still available by prescribing the Zeroderma range instead of the following alternative emollient brands.1-3,* That’s potential savings per month!
Zeroderma is manufactured in the UK by the UK’s #1 prescription emollient company4 offering reliable supply, patient choice and outstanding value.
| Current annual spend1 |
|
|---|---|
| E45® Cream | |
| Aqueous Cream | |
| Aveeno® Cream | |
| Epaderm® Ointment | |
| Hydromol® Ointment | |
| Doublebase® Gel | |
| TOTAL | |
Keep scrolling to view equivalent annual Zeroderma spend
| Equivalent annual Zeroderma spend2 |
|
|---|---|
| Zerocream® | |
| ZeroAQS® | |
| Zeroveen® | |
| Zeroderm® | |
| Zeroderm® | |
| Zerodouble® | |
| TOTAL | |
Keep scrolling to view potential savings by implementing the Zeroderma range
| Potential savings with Zeroderma3 | |
|---|---|
| SAVE | |
|
Potential Zeroderma® savings3 with an uptake of Potential savings with uptake of % |
|
|---|---|
| Zerocream® | 0 |
| ZeroAQS® | 0 |
| Zeroveen® | 0 |
| Zeroderm® | 0 |
| Zeroderm® | 0 |
| Zerodouble® | 0 |
| SAVE | 0 |
* Savings shown against alternative emollient brands that are similar in formulation to Zeroderma products and where the Zeroderma product can offer a cost saving. Zerobase not included as there is no direct comparitor.
Download Cost Savings Report
Request A Meeting
Let’s stay connected!
Join us and be the first to hear about our products, services & educational resources
References. 1. Current annual spend is based on IQVIA 12-month prescribing by volume (July 2025, data on file) × current indicative NHS list prices available from DM+D (accessed September 2025). Assumes prescribing was for 500g/ml product except Hydromol® Ointment where data for 125g and 500g prescriptions only was used for improved accuracy. 2. Equivalent annual Zeroderma spend is based on on IQVIA 12-month prescribing by volume of alternative emollient (July 2025, data on file) × current indicative NHS list prices of similar Zeroderma product available from DM+D (accessed September 2025). Assumes prescribing was for 500g/ml product except Hydromol® Ointment where data for 125g and 500g prescriptions only was used for improved accuracy. 3. Potential savings with Zeroderma calculated by subtracting equivalent annual Zeroderma spend from current annual spend. 4. IQVIA RXA Unit Sales July 2025.
